Business Context and Reporting Period
Company: Athira Pharma, Inc. (Note: Input metadata referenced "Leonabio," but the filing text identifies the registrant as Athira Pharma, Inc., trading under symbol ATHA).
Reporting Period: Quarterly period ended September 30, 2025 (Q3 2025).
Business Overview: Athira is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. The company's lead drug candidate is ATH-1105, currently in development for Amyotrophic Lateral Sclerosis (ALS). Following the failure of its previous lead candidate, fosgonimeton, to meet primary endpoints in the LIFT-AD Phase 2/3 trial in September 2024, the company paused fosgonimeton development and shifted focus to ATH-1105. The company is currently exploring strategic alternatives to maximize stockholder value.
Corporate Action: On September 17, 2025, the company effected a 1-for-10 reverse stock split to regain compliance with Nasdaq listing requirements. All share and per-share data in this filing have been restated to reflect this split.
Key Financial Metrics
| Metric (in thousands, except per share) | Q3 2025 | Q3 2024 | 9 Months Ended Sept 30, 2025 | 9 Months Ended Sept 30, 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(6,611) | $(28,741) | $(22,720) | $(81,937) |
| Net Loss Per Share (Basic & Diluted) | $(1.68) | $(7.46) | $(5.80) | $(21.33) |
| Total Operating Expenses | $6,874 | $29,621 | $23,701 | $85,336 |
| Research & Development (R&D) | $2,825 | $17,922 | $10,788 | $61,312 |
| General & Administrative (G&A) | $4,049 | $7,572 | $12,913 | $19,897 |
| Cash, Cash Equivalents & Investments | $25,226 | $51,275 | $25,226 (as of Sept 30, 2025) | $77,860 (as of Sept 30, 2024) |
| Accumulated Deficit | $(428,866) | $(391,143) | $(428,866) | $(391,143) |
| Net Cash Used in Operating Activities (9 Months) | $(26,332) | $(71,157) | $(26,332) | $(71,157) |
Material Changes vs. Prior Period
- Significant Expense Reduction: Total operating expenses decreased by 77% in Q3 2025 compared to Q3 2024 ($6.9M vs. $29.6M). This was driven primarily by the cessation of the fosgonimeton program following the LIFT-AD trial results.
- R&D Costs: R&D expenses dropped 84% in Q3 2025 ($2.8M vs. $17.9M). The decrease was attributed to a $9.8M reduction in fosgonimeton program costs and a $1.8M reduction in ATH-1105 costs.
- Legal Expenses: Legal expenses were $0 in Q3 2025, compared to $4.1M in Q3 2024, reflecting the resolution of prior legal matters.
- Liquidity Position: Cash and investments decreased from $51.3M at September 30, 2024, to $25.2M at September 30, 2025, due to operating cash burn. However, the burn rate has significantly slowed.
- Stock Structure: The 1-for-10 reverse stock split reduced the number of outstanding shares to approximately 3.94 million.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management estimates that existing cash, cash equivalents, and investments of $25.2 million are sufficient to fund operating expenses and capital expenditure requirements through at least the next 12 months (into late 2026).
- Strategic Alternatives: The company is actively exploring strategic alternatives, including potential mergers, acquisitions, business combinations, or asset sales, to maximize stockholder value. No definitive transaction has been agreed upon.
- Development Focus: The company has paused fosgonimeton development. Future efforts are concentrated on ATH-1105 for ALS. The company has completed a Phase 1 trial for ATH-1105 showing a favorable safety profile and is preparing for future clinical trials.
- Capital Needs: The company will require substantial additional funding to complete the development and commercialization of ATH-1105. It has an "at-the-market" (ATM) equity offering facility available up to $75.0 million, though no securities have been sold under this facility to date.
- Key Risks:
- Development Risk: ATH-1105 may fail to demonstrate safety or efficacy in future trials.
- Strategic Transaction Risk: There is no assurance that the strategic review process will result in a transaction or that any transaction will be completed on attractive terms.
- Regulatory Risk: FDA approval processes are lengthy and unpredictable; failure to obtain approval will prevent commercialization.
- Intellectual Property: Reliance on in-licensed patents (e.g., from Washington State University) and the risk of patent challenges.
Investor Verification Checklist
- Cash Runway: Verify the $25.2M cash balance and the 12-month runway estimate against current burn rates, considering potential costs associated with the strategic review process.
- Strategic Process Status: Monitor for updates on the strategic alternatives review, including any definitive agreements or termination of the process.
- ATH-1105 Timeline: Confirm the timeline for the initiation of the next clinical trial for ATH-1105 in ALS patients.
- Reverse Stock Split Impact: Assess the post-split trading liquidity and market price stability of the common stock.
- Legal Contingencies: Review the status of any remaining legal proceedings or investigations, particularly those related to prior research misconduct claims involving former executives.
- ATM Facility Usage: Monitor whether the company utilizes its $75M ATM facility to raise capital, which could lead to shareholder dilution.